These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3387517)

  • 1. Naltrexone in infantile autism.
    Campbell M; Adams P; Small AM; Tesch LM; Curren EL
    Psychopharmacol Bull; 1988; 24(1):135-9. PubMed ID: 3387517
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of naltrexone in autistic children: report of two cases.
    Akkök F
    Turk J Pediatr; 1995; 37(1):19-23. PubMed ID: 7732604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
    Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
    Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone in children with autism.
    Buitelaar JK; Willemsen-Swinkels S; Van Engeland H
    J Am Acad Child Adolesc Psychiatry; 1998 Aug; 37(8):800-2. PubMed ID: 9695440
    [No Abstract]   [Full Text] [Related]  

  • 5. Naltrexone open trial with a 5-year-old-boy. A social rebound reaction.
    Lensing P; Klingler D; Lampl C; Leboyer M; Bouvard M; Plumet MH; Panksepp J
    Acta Paedopsychiatr; 1992; 55(3):169-73. PubMed ID: 1414352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.
    Ernst M; Devi L; Silva RR; Gonzalez NM; Small AM; Malone RP; Campbell M
    Psychopharmacol Bull; 1993; 29(2):221-7. PubMed ID: 8290669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder.
    Elchaar GM; Maisch NM; Augusto LM; Wehring HJ
    Ann Pharmacother; 2006 Jun; 40(6):1086-95. PubMed ID: 16735648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psychopharmacology of autism].
    Chabrol H; Bonnet D; Roge B
    Encephale; 1996; 22(3):197-203. PubMed ID: 8767048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief report: a double-blind study of naltrexone in infantile autism.
    Leboyer M; Bouvard MP; Launay JM; Tabuteau F; Waller D; Dugas M; Kerdelhue B; Lensing P; Panksepp J
    J Autism Dev Disord; 1992 Jun; 22(2):309-19. PubMed ID: 1345670
    [No Abstract]   [Full Text] [Related]  

  • 10. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone.
    Scifo R; Cioni M; Nicolosi A; Batticane N; Tirolo C; Testa N; Quattropani MC; Morale MC; Gallo F; Marchetti B
    Ann Ist Super Sanita; 1996; 32(3):351-9. PubMed ID: 9028057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on naltrexone on infantile autism.
    Leboyer M; Bouvard MP; Dugas M
    Lancet; 1988 Mar; 1(8587):715. PubMed ID: 2895254
    [No Abstract]   [Full Text] [Related]  

  • 12. Naltrexone plasma levels, clinical response and effect on weight in autistic children.
    Gonzalez NM; Campbell M; Small AM; Shay J; Bluhm LD; Adams PB; Foltz RL
    Psychopharmacol Bull; 1994; 30(2):203-8. PubMed ID: 7831456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause?
    Good P
    Med Hypotheses; 2006; 67(3):671-2. PubMed ID: 16759815
    [No Abstract]   [Full Text] [Related]  

  • 14. [Opiate hypothesis of the origin of early childhood autism and sequelae for psychopharmacotherapy].
    Lensing P; Klingler D; Panksepp J; Huber M; Saria A; Hackenberg B; Adam H
    Z Kinder Jugendpsychiatr; 1992 Sep; 20(3):185-96. PubMed ID: 1329399
    [No Abstract]   [Full Text] [Related]  

  • 15. Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management.
    Williams PG; Allard A; Sears L; Dalrymple N; Bloom AS
    J Autism Dev Disord; 2001 Feb; 31(1):103-8. PubMed ID: 11439748
    [No Abstract]   [Full Text] [Related]  

  • 16. Resolved: autistic children should have a trial of naltrexone.
    Campbell M; Harris JC
    J Am Acad Child Adolesc Psychiatry; 1996 Feb; 35(2):246-9; discussion 249-51. PubMed ID: 8720635
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
    Willemsen-Swinkels SH; Buitelaar JK; van Engeland H
    Biol Psychiatry; 1996 Jun; 39(12):1023-31. PubMed ID: 8780837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design.
    Willemsen-Swinkels SH; Buitelaar JK; van Berckelaer-Onnes IA; van Engeland H
    J Autism Dev Disord; 1999 Apr; 29(2):167-9. PubMed ID: 10382138
    [No Abstract]   [Full Text] [Related]  

  • 19. Theoretical aspects of the study of benzodiazepine receptors in infantile autism.
    Garreau B; Herry D; Zilbovicius M; Samson Y; Guerin P; Lelord G
    Acta Paedopsychiatr; 1993; 56(2):133-8. PubMed ID: 8135112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.